Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the associations of self-compassion and self-efficacy levels with symptom severity, functional status, and quality of life in individuals with Parkinson's disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Self-Report Questionnaire Assessment | Other | This study does not involve any therapeutic intervention. Participants will complete a set of self-report questionnaires assessing self-compassion, self-efficacy, symptom severity, functional status, and quality of life. Data will be collected in a single session for observational analysis. |
| Measure | Description | Time Frame |
|---|---|---|
| Self-Compassion Scale (SCS) Total Score | Self-compassion will be measured using the Self-Compassion Scale (SCS), a validated self-report instrument assessing multiple dimensions of self-compassion. The total score will be calculated, with higher scores indicating greater self-compassion. | Baseline (at the time of questionnaire completion) |
| Self-Efficacy for Managing Chronic Disease 6-Item Scale Total Score | Self-efficacy will be measured using the Self-Efficacy for Managing Chronic Disease 6-Item Scale, a validated self-report measure. The total score will be calculated, with higher scores indicating greater perceived self-efficacy. | Baseline (at the time of questionnaire completion) |
| Unified Parkinson's Disease Rating Scale (UPDRS) Total Score | Symptom severity will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), a validated clinician-rated instrument assessing motor and non-motor symptoms. Higher total scores indicate greater disease severity. | Baseline (at the time of questionnaire completion) |
| Measure | Description | Time Frame |
|---|---|---|
| Timed Up and Go (TUG) Test Completion Time in Seconds | Functional mobility will be measured using the Timed Up and Go (TUG) test. The time required to stand up from a chair, walk 3 meters, turn, return, and sit down will be recorded in seconds. Longer times indicate poorer functional mobility. | Baseline (at the time of questionnaire completion) |
Not provided
Inclusion Criteria:
Hoehn and Yahr stage 1-3
Age between 40 and 85 years
Sufficient cognitive function to communicate (Mini-Mental State Examination [MMSE] score ≥ 24)
Patients attending the Movement Disorders Outpatient Clinic of the Neurology Department
Willingness to participate and provide informed consent
Exclusion Criteria:
Diagnosis of advanced dementia
Presence of uncontrolled systemic chronic diseases (e.g., diabetes mellitus, hypertension) or severe cardiovascular or respiratory conditions
Presence of additional orthopedic or neurological conditions that may affect test performance
Severe visual or hearing impairments that could interfere with assessments
Inability to cooperate adequately with the physiotherapist during assessments
Not provided
Not provided
Not provided
The study population will consist of individuals diagnosed with Parkinson's disease who are classified as Hoehn and Yahr stage 1-3, aged between 40 and 85 years, and have sufficient cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Six-Minute Walk Test (6MWT) Distance in Meters | Functional exercise capacity will be measured using the Six-Minute Walk Test (6MWT). The total distance walked in six minutes will be recorded in meters. Greater distances indicate better functional capacity. | Baseline (at the time of questionnaire completion) |
| Mini-Balance Evaluation Systems Test (Mini-BESTest) Total Score | Dynamic balance will be measured using the Mini-Balance Evaluation Systems Test (Mini-BESTest), a 14-item performance-based assessment. Total scores range from 0 to 28, with higher scores indicating better balance performance. | Baseline (at the time of questionnaire completion) |
| Parkinson's Disease Questionnaire-39 (PDQ-39) Total Score | Quality of life will be measured using the Parkinson's Disease Questionnaire-39 (PDQ-39), a validated disease-specific instrument. Total scores range from 0 to 100, with higher scores indicating poorer quality of life. | Baseline (at the time of questionnaire completion) |
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
Not provided
Not provided